The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

• Главные авторы: Yue Pan (Автор), Yucheng Fu (Автор), Yue Zeng (Автор), Xiaohan Liu (Автор), Yurong Peng (Автор), Chunhong Hu (Автор), Chao Deng (Автор), Zhenhua Qiu (Автор), Jian Zou (Автор), Yuxuan Liu (Автор), Fang Wu (Автор)
• Формат: ‌
• Опубликовано: BMC, 2022-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and a...